As of Nov 19, 2026, 2 of 2 active firms rate RNXT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RNXT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.04
Range $-0.06 – $-0.03 · 2 analysts · -44% YoY
Next period, 2 analysts expect RenovoRx Inc to earn $-0.04 a share (range $-0.06 – $-0.03), versus $-0.08 a year earlier. Full-year consensus is $-0.27, growing to $-0.12 the year after.
REVENUE · NEXT QUARTER
$1.4M
Range $1.3M – $1.5M · 2 analysts · +148% YoY
Revenue is expected to reach $1.4M (range $1.3M – $1.5M), +147.6% year-over-year. Full-year consensus is $3.9M, rising to $10.5M next year.
Top analysts covering RenovoRx Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RNXT.
#1
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$3.00+171.5% to target
Overall win rate
38%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #567
Buy
$4.00+262.0% to target
Overall win rate
30%
+ Follow
#3
Edward Woo
Ascendiant Capital · Rank #570
Buy
$14.50+1212.2% to target
Overall win rate
24%
+ Follow
#4
SH
Scott Henry
Alliance Global Partners
Buy
$3.00+171.5% to target
Coverage
—
+ Follow
RNXT stock forecast FAQ
What is RNXT's average 12-month price target?+
The 2 active firms with a live target average $8.75 for RenovoRx Inc over the next 12 months, ranging from a $14.50 high to a $3.00 low, as of Nov 19, 2026.
Is RNXT stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RNXT?+
The Street-high target is $14.50 (Ascendiant Capital), and the Street-low is $3.00 (HC Wainwright & Co.). The average of all 2 active-firm targets is $8.75.
How many active Wall Street firms cover RNXT?+
2 active firms have a recognized rating on RenovoRx Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RNXT?+
Among analysts who currently cover RNXT, Swayampakula Ramakanth of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #321). Their current call is Buy with a $3.00 target.
What is RenovoRx Inc's projected EPS for next quarter?+
The consensus estimate is $-0.04 per share (range $-0.06 – $-0.03) across 2 analysts. Full-year EPS is projected at $-0.27, rising to $-0.12 the following year.
How much revenue is RenovoRx Inc expected to report next quarter?+
Consensus revenue is $1.4M (range $1.3M – $1.5M). Full-year revenue is projected at $3.9M, growing to $10.5M next year.
Have analysts been upgrading or downgrading RNXT lately?+
As of Nov 19, 2026, 2 of 2 active firms rate RNXT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RNXT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.